Clinical trials · New York
Solid Tumor clinical trials in New York
We’re tracking 283 recruiting solid tumor studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT07164313RecruitingPhase 1
ZW251 for advanced solid tumors
This trial is testing a new drug called ZW251 for people with advanced liver cancer (hepatocellular carcinoma), non-small cell lung cancer, or germ cell tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
New York, New YorkAges 18 years+ - NCT05735080RecruitingPhase 1/Phase 2
INX-315 for advanced cancers with a specific gene change
This trial studies an experimental medicine (INX-315) given in an “open-label” way to people with advanced cancer that has not responded to prior treatment. It mainly looks at safety and side effects first, and also checks how well it works in cancers with a specific gene amplification.
Buffalo, New YorkAges 18 years+ - NCT02693535RecruitingPhase 2
Targeted drug testing for advanced cancer with tumor gene changes
This trial tests whether FDA-approved targeted drugs can help people with advanced cancer whose tumors have specific gene changes. It aims to match your tumor's unique genetic profile to a drug that may work better for you.
Lake Success, New YorkAges 12 years+ - NCT06413680RecruitingPhase 1/Phase 2
Study of REGN10597 with or without cemiplimab for advanced solid tumors
This study tests a new drug called REGN10597, either alone or with cemiplimab, for people with advanced solid tumors (like melanoma or kidney cancer) that have not responded to standard treatments. The goal is to see if the combination can shrink tumors or slow their growth.
Lake Success, New YorkAges 18 years+ - NCT06673329RecruitingPhase 1
Brodalumab for immune-related side effects from cancer treatment
This trial tests if brodalumab, an antibody that blocks a specific immune pathway (IL-17), can help control side effects caused by immunotherapy cancer treatment. It is for people with advanced solid organ cancers who have immune-related side effects that are suspected to involve IL-17.
New York, New YorkAges 18 years+ - NCT06427941RecruitingPhase 1/Phase 2
Study of BGB-B2033 with other drugs for advanced solid tumors
This study tests a new drug called BGB-B2033, alone or with other drugs (tislelizumab and bevacizumab), in people with certain advanced cancers. The goal is to see if this combination can shrink tumors or slow their growth, and to check its safety.
New York, New YorkAges 18 years+ - NCT03486873RecruitingPhase 3
Study extension for people on pembrolizumab, testing long-term safety
This trial follows people with advanced tumors who are already on pembrolizumab (or similar treatment) to check long-term safety and effectiveness. It may help your care team by monitoring benefits and side effects over a longer period.
New York, New YorkAges 18 years+ - NCT06605404Recruiting
Pan-tumor study of a blood test after cancer surgery
This study is testing a new blood test that looks for leftover cancer cells after surgery. It is for people with different types of solid tumors who are planning to have surgery to cure their cancer. The goal is to see if the test can help guide future treatment decisions.
Binghamton, New YorkAges 18 years+ - NCT00736749Recruiting
Long-term health check for childhood cancer survivors
This trial tracks the long-term health of people who took part in previous Children's Oncology Group studies. It helps doctors understand the lasting effects of cancer treatment and improve care for survivors.
Albany, New YorkAges Any age - NCT05947695Recruiting
Nurse-led comfort and survivorship care for advanced cancer
This study looks at whether a specialized nurse-led care plan soon after diagnosis/treatment helps people living with advanced (metastatic) cancer. It focuses on patients expected to do better than average based on certain prognosis factors.
West Islip, New YorkAges 21 years+ - NCT04787042RecruitingPhase 1/Phase 2
Safety and early benefits of ST-067 for advanced solid tumors
This early-stage trial tests ST-067 to see if it is safe and whether it may shrink advanced cancers. It also looks at how the drug moves through the body and affects the immune system.
Buffalo, New YorkAges 18 years+ - NCT07630974RecruitingPhase 1/Phase 2
New Cancer Drug for Children With Hard-to-Treat Solid Tumors
This trial tests a new drug called ifinatamab deruxtecan in children whose solid tumors (cancers that form lumps, excluding brain tumors) have come back or stopped responding to previous treatments. The drug is designed to target and kill cancer cells while potentially causing fewer side effects than standard chemotherapy.
New York, New YorkAges 1 month–17 years - NCT07593092RecruitingPhase 1
Testing new cancer immunotherapy for advanced ovarian cancer
This study tests two new experimental drugs (XmAb541 and XmAb808) designed to fight advanced ovarian cancer by activating your immune system. You'll be closely monitored to see how safe the drugs are and how your body tolerates them.
Lake Success, New YorkAges 18 years+ - NCT07563829RecruitingPhase 1
NPX372 immunotherapy for advanced solid tumors
This trial tests NPX372, a new type of immunotherapy designed to fight several types of advanced cancer that haven't responded to standard treatments. It works by combining two immune signals to help your body's immune system recognize and attack cancer cells.
The Bronx, New YorkAges 19 years+ - NCT07540572RecruitingPhase 1
Testing IDE574 safety and effectiveness in advanced solid tumors
This early-stage trial tests a new drug called IDE574 to see if it is safe and effective in treating advanced cancers that have spread or stopped responding to standard treatments. The trial focuses mainly on hormone-receptor positive breast cancer, but also includes lung, prostate, and colorectal cancers.
Lake Success, New YorkAges 18–99 - NCT07525141RecruitingPhase 1
Testing JNJ-1761981 for advanced solid tumors
This early-stage trial tests a new drug called JNJ-1761981 in people with solid tumors (cancers that form in organs or tissues, excluding brain tumors) that have spread or returned after standard treatment. The study aims to find the right dose and see how well the drug works.
The Bronx, New YorkAges 18 years+ - NCT07532902RecruitingPhase 1
BMS-986504 with standard treatment for advanced solid tumors
This trial tests a new drug called BMS-986504 alongside standard treatments for certain advanced cancers (mesothelioma, stomach/esophageal cancer, or bladder cancer). The drug targets a specific genetic change (MTAP deletion) that may make cancer cells more vulnerable to treatment. Joining could help you access a new therapy, but it may not be suitable for everyone.
Commack, New YorkAges 18 years+ - NCT07522073RecruitingPhase 3
Chemotherapy with or without KRAS inhibitor for pancreatic cancer
This study tests whether adding a new drug called INCB161734 to standard chemotherapy helps people with advanced pancreatic cancer that has a specific genetic change (KRAS G12D mutation). You would be randomly assigned to receive either chemotherapy alone or chemotherapy plus the new drug.
Lake Success, New YorkAges 18 years+ - NCT07503808RecruitingPhase 1
IDE034 for advanced solid tumors with B7-H3 or PTK7
This study tests a new drug called IDE034 for people with advanced solid tumors that have certain markers (B7-H3 and PTK7). The drug may help by targeting these markers on cancer cells, and the study checks if it is safe and effective.
Lake Success, New YorkAges 18 years+ - NCT07486713RecruitingPhase 4
Olutasidenib drug interaction study for IDH1 mutation cancers
This trial tests how olutasidenib interacts with other drugs in people with cancers that have an IDH1 mutation, like certain leukemias or brain tumors. Participation may help determine the best way to take this treatment safely.
New York, New YorkAges 18 years+ - NCT07488676RecruitingPhase 1/Phase 2
Study of ASP546C for stomach, pancreas, and other cancers
This trial tests a new drug called ASP546C in people with certain advanced cancers that have a specific marker (CLDN18.2). It aims to see if the drug can shrink or slow tumor growth.
Lake Success, New YorkAges 18 years+ - NCT07470853RecruitingPhase 1
Study of HWK-016 for advanced ovarian or endometrial cancer
This trial tests a new drug called HWK-016, which is designed to target and deliver medicine directly to cancer cells that have a specific marker (MUC16). It is for people with advanced ovarian or endometrial cancer to see if it can shrink tumors or slow their growth.
Long Island City, New YorkAges 18 years+ - NCT07454642RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests a new drug called AVA6103 for people with certain advanced solid tumors that have not responded to standard treatments. The drug may help by targeting a protein on cancer cells and interfering with their ability to multiply.
New York, New YorkAges 18 years+ - NCT07444814RecruitingPhase 1
HWK-007 for advanced solid tumors
This trial tests a new drug called HWK-007, which is designed to target and attack cancer cells while sparing healthy ones. It is for people with specific advanced solid tumors (lung, endometrial, or ovarian cancer) that have not responded well to standard treatments.
Buffalo, New YorkAges 18 years+
Solid Tumor trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting solid tumor studies listed above.
- Memorial Sloan Kettering Cancer Center · 7 studies
- Montefiore Medical Center · 3 studies
- Roswell Park Comprehensive Cancer Center · 3 studies
- Columbia University Irving Medical Center · 2 studies
- START New York Long Island, LLC · 2 studies
- Albany Medical Center
- Cohen Children's Medical Center
- Columbia University Irving Medical Center / NewYork-Presbyterian
What taking part in a solid tumor study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Solid Tumor trials in other states
Common questions
- Are there solid tumor clinical trials in New York?
- Yes. We're currently tracking 283 recruiting solid tumor studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a solid tumor study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a solid tumor trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New solid tumor studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.